First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow's Growing Ocular Surface Franchise
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten ratings firms that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at two major eyecare meetings: American Academy of Optometry's (AAOpt) Annual meeting taking place September 30 – October 3, 2026, in Anaheim, California; and American Academy of Ophthalmology's (AAO) Annual Meeting, taking place October 9–12, 2026, in New Orleans, Louisiana.
Shares of Harrow, Inc. (NASDAQ: HROW - Get Free Report) dropped 6.8% during trading on Monday. The company traded as low as $31.64 and last traded at $30.8280. Approximately 176,792 shares were traded during trading, a decline of 75% from the average daily volume of 699,208 shares. The stock had previously closed at $33.07. Wall Street
Harrow (NASDAQ: HROW - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Insider and Institutional Ownership 72.8% of Harrow shares are
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following three investor conferences in September in New York, NY: 2026 Cantor Global Healthcare Conference Format: Fireside chat + 1x1 investor meetings Date/Time: Wednesday, September 9, 2026, at 1:35 p.m.
Ophthalmic disease management company Harrow Inc. (NASDAQ:HROW) on Thursday shared outcomes from a prospective, randomized, contralateral-eye clinical study.
Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest
Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript
Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.
